Wave Life Sciences (WVE) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic pipeline and clinical updates

• Advancements in oligonucleotide and RNA medicine chemistry are converging with human clinical genetics to unlock new therapeutic targets, notably in obesity and RNA editing.

• Clinical data for Inhibin βE siRNA in obesity show promising fat loss, especially visceral fat, with preservation of lean mass, and upcoming data will further clarify dose and time dependencies.

• RNA editing programs, such as for alpha-1 antitrypsin deficiency, demonstrate robust protein correction and potential for accelerated regulatory pathways.

• Phase 2a studies are being accelerated to include higher BMI and comorbid patients, with expanded biomarker and imaging endpoints to assess broader metabolic impacts.

• Early discovery efforts focus on bifunctional modalities and dual tissue targeting, aiming for single-molecule therapies that address multiple cardiometabolic pathways.

Clinical differentiation and regulatory strategy

• Obesity therapy emphasizes improving body composition by reducing visceral fat while preserving muscle, addressing key unmet needs highlighted by KOLs and patient advocates.

• Maintenance therapy with infrequent dosing (once or twice yearly) is positioned as a major advantage over current weekly or monthly regimens, potentially improving compliance and outcomes.

• Regulatory engagement aims to incorporate body composition and visceral fat reduction into clinical endpoints and labeling, leveraging recent FDA draft guidance and published literature.

• The RNA editing platform avoids off-target protein production and delivery vehicle-related inflammation, supporting a favorable safety and efficacy profile.

• Accelerated approval is being pursued for alpha-1 antitrypsin deficiency, with a focus on biomarker-driven registration and expansion to broader patient populations through genetic testing.

Commercial outlook and scalability

• Scalability of RNA medicines is improving due to advances in synthesis and raw material costs, supporting large-scale indications like obesity and cardiovascular disease.

• Pricing strategy is expected to reflect the differentiated profile of infrequent dosing, muscle preservation, and broad accessibility.

• Strategic interest is high for both monotherapy and combination approaches, with segmentation opportunities for specific populations such as older adults and those at risk for muscle loss.

• Maintenance and combination use with GLP-1s are seen as key growth areas, with potential to transition patients from existing therapies.

• Expanded indications, including MASH and other metabolic diseases, are being explored based on the impact on visceral and liver fat.